Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 4 (2007), Issue 5 (May)

1. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.
   J Infect Dis, 195(11): 1582-9. [Abstract] [Full-text]
2. New advances in vaccine technology and improved cervical cancer prevention.
   Obstet Gynecol, 109(5): 1187-92. [Abstract] [Full-text]
3. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.
   Clin Cancer Res, 13(9): 2599-605. [Abstract] [Full-text]
4. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells.
   Clin Cancer Res, 13(9): 2568-76. [Abstract] [Full-text]
5. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.
   J Clin Microbiol, 45(5): 1447-54. [Abstract] [Full-text]
6. Intrabody strategies for the treatment of human papillomavirus-associated disease.
   Expert Opin Biol Ther, 7(5): 677-89. [Abstract] [Full-text]
7. Genetic variation of antigen processing machinery components and association with cervical carcinoma.
   Genes Chromosomes Cancer, 46(6): 577-86. [Abstract] [Full-text]
8. Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion.
   Cancer Lett, 251(2): 211-9. [Abstract] [Full-text]
9. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
   N Engl J Med, 356(19): 1915-27. [Abstract] [Full-text]
10. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients.
    Arthritis Rheum, 57(4): 619-25. [Abstract] [Full-text]
11. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).
    Int J Radiat Oncol Biol Phys, 68(2): 485-90. [Abstract] [Full-text]
12. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours.
    Int J Radiat Oncol Biol Phys, 68(2): 491-8. [Abstract] [Full-text]
13. New HPV-16 European and non-European variants in Central Brazil.
    Virus Genes, 35(1): 1-4. [Abstract] [Full-text]
14. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.
    Int J Immunogenet, 34(3): 213-7. [Abstract] [Full-text]
15. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.
    Cancer Res, 67(10): 4605-19. [Abstract] [Full-text]
16. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Clin Obstet Gynecol, 50(2): 313-23. [Abstract] [Full-text]
17. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Lancet, 369(9574): 1693-702. [Abstract] [Full-text]
18. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis.
    Gynecol Oncol, 105(3): 571-7. [Abstract] [Full-text]
19. Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.
    Gynecol Oncol, 105(3): 757-61. [Abstract] [Full-text]
20. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study.
    Gynecol Oncol, 105(3): 609-19. [Abstract] [Full-text]
21. Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma.
    Gynecol Oncol, 105(3): 593-9. [Abstract] [Full-text]
22. HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population.
    Gynecol Oncol, 105(3): 736-41. [Abstract] [Full-text]
23. Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
    Gynecol Oncol, 105(3): 823-5. [Abstract] [Full-text]
24. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
    Gynecol Oncol, 105(3): 662-6. [Abstract] [Full-text]
25. Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.
    Gynecol Oncol, 105(3): 635-40. [Abstract] [Full-text]
26. Laparoscopic radical hysterectomy using pulsed bipolar system: comparison with conventional bipolar electrosurgery.
    Gynecol Oncol, 105(3): 620-4. [Abstract] [Full-text]
27. Detection of the gonadal veins in the diagnosis of transposed ovaries in patients with cervical carcinoma: a useful sign on MDCT.
    AJR Am J Roentgenol, 188(6): 1564-7. [Abstract] [Full-text]
28. On verification of hyperthermia treatment planning for cervical carcinoma patients.
    Int J Hyperthermia, 23(3): 303-14. [Abstract] [Full-text]
29. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age.
    Sex Transm Dis, 34(6): 371-7. [Abstract] [Full-text]
30. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
    Int J Cancer, 121(2): 361-7. [Abstract] [Full-text]
31. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.
    J Adolesc Health, 40(6): 564-71. [Abstract] [Full-text]
32. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine.
    J Adolesc Health, 40(6): 559-63. [Abstract] [Full-text]
33. Hybridization assay performed at ambient temperature for typing high-risk human papillomaviruses.
    J Clin Virol, 39(2): 113-8. [Abstract] [Full-text]
34. Characterization and experimental transmission of an oncogenic papillomavirus in female macaques.
    J Virol, 81(12): 6339-45. [Abstract] [Full-text]
35. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese.
    J Med Virol, 79(7): 970-6. [Abstract] [Full-text]
36. Expression of IP-10 related to angiogenesis in uterine cervical cancers.
    Br J Cancer, 96(11): 1735-9. [Abstract] [Full-text]
37. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
    Biochem Pharmacol, 74(1): 28-40. [Abstract] [Full-text]
38. Magnetic resonance imaging of the cervix.
    Cancer Imaging, 7: 69-76. [Abstract] [Full-text]
39. Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy.
    Nat Clin Pract Oncol, 4(6): 375-80. [Abstract] [Full-text]
40. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer.
    Nat Clin Pract Oncol, 4(6): 353-61. [Abstract] [Full-text]
41. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.
    Int J Cancer, 121(3): 621-32. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.